MARKET

ACAD

ACAD

ACADIA Pharm
NASDAQ

Real-time Quotes | Nasdaq Last Sale

17.02
+0.31
+1.86%
After Hours: 16.77 -0.25 -1.47% 17:17 09/21 EDT
OPEN
16.75
PREV CLOSE
16.71
HIGH
17.32
LOW
16.61
VOLUME
1.23M
TURNOVER
--
52 WEEK HIGH
57.46
52 WEEK LOW
15.68
MARKET CAP
2.73B
P/E (TTM)
-10.3572
1D
5D
1M
3M
1Y
5Y
The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 13)
Benzinga · 09/14 11:50
Acadia (ACAD) Down 10.8% Since Last Earnings Report: Can It Rebound?
Zacks.com · 09/03 15:31
Biotech Is Due for a Comeback. 5 Stocks That Could Lead a Revival.
marketwatch.com · 09/03 08:15
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO, September 02, 2021--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming investor conferences:
Business Wire · 09/02 13:00
BRIEF-Acadia Pharmaceuticals Inc Says Mark Schneyer Has Been Appointed Acadia's Interim Chief Financial Officer
reuters.com · 09/01 21:10
Acadia Pharmaceuticals Announces Executive Leadership Change
SAN DIEGO, September 01, 2021--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Elena Ridloff, Executive Vice President and Chief Financial Officer (CFO), will be leaving the company effective September 10, 2021 to join another biopharmaceut...
Business Wire · 09/01 20:05
Acadia Pharmaceuticals CFO to Leave
MT Newswires · 09/01 16:32
Dermata therapeutics appoints Kyri Van Hoose as CFO
Dermata Therapeutics (NASDAQ:DRMA) appoints  Kyri Van Hoose as Senior Vice President, Chief Financial Officer. Ms. Van Hoose is a strategic and operational finance leader with over 20 years of experience, including
Seekingalpha · 09/01 10:55
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ACAD. Analyze the recent business situations of ACADIA Pharm through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 21 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ACAD stock price target is 25.53 with a high estimate of 35.00 and a low estimate of 18.00.
EPS
Institutional Holdings
Institutions: 389
Institutional Holdings: 162.87M
% Owned: 101.38%
Shares Outstanding: 160.64M
TypeInstitutionsShares
Increased
83
18.19M
New
41
1.94M
Decreased
71
9.90M
Sold Out
67
7.92M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.43%
Pharmaceuticals & Medical Research
+0.74%
Key Executives
Non-Executive Chairman/Independent Director
Stephen Biggar
President
Srdjan Stankovic
Chief Executive Officer/Chief Financial Officer/Director
Stephen Davis
Chief Financial Officer/Executive Vice President
Elena Ridloff
Executive Vice President/General Counsel/Secretary
Austin Kim
Director
Elizabeth Garofalo
Independent Director
Julian Baker
Independent Director
Laura Brege
Independent Director
James Daly
Independent Director
Edmund Harrigan
Independent Director
Daniel Soland
No Data
  • All
  • Financials
  • Insiders
More
About ACAD
ACADIA Pharmaceuticals Inc. (ACADIA) is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines to address the medical needs in central nervous system disorders. The Company's lead product, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. ACADIA’s developments are focused on pimavanserin for additional neuropsychiatric conditions, trofinetide for Rett syndrome, ACP-044 for pain management and an early-stage muscarinic receptor program.

Webull offers kinds of ACADIA Pharmaceuticals Inc. stock information, including NASDAQ:ACAD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACAD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ACAD stock methods without spending real money on the virtual paper trading platform.